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Background: Tissue injury due to hypoxia and/or free radicals is common in a variety of disease processes. This
cross-sectional study aimed to investigate effect of chronic kidney diseases (CKD) and hemodialysis (HD) on hypoxia
and oxidative stress biomarkers.
Methods: Forty pediatric patients with CKD on HD and 20 healthy children were recruited. Plasma hypoxia induced
factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) were measured by specific ELISA kits while, total
antioxidant capacity (TAC), total peroxide (TPX), pyruvate and lactate by enzymatic/chemical colorimetric methods.
Oxidative stress index (OSI) and lactate/pyruvate (L/P) ratio were calculated.
Results: TAC was significantly lower while TPX, OSI and VEGF were higher in patients at before- and after-dialysis
session than controls. Lactate and HIF-1α levels were significantly higher at before-dialysis session than controls.
Before dialysis, TAC and L/P ratio were lower than after-dialysis. In before-dialysis session, VEGF correlated positively
with pyruvate, HIF-1α and OSI correlated positively with TPX, but, negatively with TAC. In after-dialysis session,
HIF-1α correlated negatively with TPX and OSI; while, OSI correlated positively with TPX.
Conclusions: CKD patients succumb considerable tissue hypoxia with oxidative stress. Hemodialysis ameliorated
hypoxia but lowered antioxidants as evidenced by decreased levels of HIF-1α and TAC at before- compared to
after-dialysis levels.Background
In chronic kidney diseases (CKD), as a worldwide public
health problem, there is a functional loss of renal glom-
eruli caused by glomerular or interstitial renal diseases
[1]. Endothelial dysfunction and cardiovascular disease
are the major cause of mortality in patients on mainten-
ance hemodialysis (HD) and peritoneal dialysis (PD) [2].
Endothelial dysfunction could be a consequence of accu-
mulation of uremic toxins functioning as inhibitors of
endothelial function (Cross et al., 2001). Pathogenetic
role for impaired vasculogenesis and reduction in peri-
tubular capillary density in the progression of CKD was
demonstrated in animal models and human studies [3].
Hypoxia is a state of reduced oxygen pressure below a
critical threshold, which restricts the function of organs,
tissues and cells. A decrease in oxygen tensions of the* Correspondence: eah3a2010@yahoo.com
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reproduction in any medium, provided the orkidney was demonstrated in a number of experimental
models of CKD. This led to the broad recognition that
chronic cellular hypoxia of the kidney is the final com-
mon pathway in the progression of CKD leading to
eventual kidney failure [4]. A group of transcription fac-
tors, designated hypoxia inducible transcription factors,
are specifically induced by low tissue oxygen tension and
are likely to have a role in the oxygen-sensing mechan-
ism and reparative reaction. Hypoxia induced factor-1
(HIF-1) is a heterodimeric protein consisting of an alpha
subunit (with 3 isoforms -1α, -2α and -3α), and a beta
subunit (also known as the aryl hydrocarbon receptor
nuclear translocator, ARNT), which is constitutively
expressed [5]. In normoxia, the regulatory HIF-1α
subunit is hydroxylated on two prolines by iron
dependent prolyl-hydroxylases to be degraded through
the ubiquitin-proteasome pathway - via its interaction
with the von Hippel-Lindau tumor suppressor protein.
Under cellular hypoxia, inhibition of such hydroxylasesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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heterodimerizes with HIF-1β and binds to the hypoxic
response elements of target gene regulatory sequences.
This induces the transcription of genes implicated in the
control of metabolism and angiogenesis, as well as apop-
tosis and cellular stress response [6].
Genes activated by HIF can be schematically classified
into three functional groups that could halt CKD pro-
gression. (1) Proteins participating in erythropoiesis,
thereby increasing tissue oxygen delivery, e.g., erythro-
poietin, transferrin, transferrin receptor, heme oxyge-
nase-1. (2) Proteins that increase local oxygen delivery
to tissues, e.g., inducible nitric oxide synthesis and vas-
cular endothelial growth factor (VEGF). (3) Proteins
required for adaptation to anaerobic cellular metabolism:
glucose transporter-1 and most glycolytic enzymes [7].
VEGF, a 35kDa molecule, is a chemoattractant that
enables the homing of regenerative endothelial cells into
local vascular lesions [8]. In the aging kidneys, loss of
VEGF expression in podocytes was associated with the
reduced number of endothelial progenitor cells [9].
However, there is still a considerable debate over the
vasculoprotective vs. pro-inflammatory effects of VEGF
[10]. VEGF is known to play multiple roles in normal
renal physiology and renal disorders. In the kidney,
VEGF is expressed in the visceral epithelial cells of
glomeruli, proximal and distal convoluted tubules and
can induce nephrogenesis and vasculogenesis. It pro-
motes cellular proliferation, differentiation, and survival
and contributes to interstitial matrix remodeling [11].
Oxidative stress is an imbalanced generation of react-
ive oxygen species (ROS) vs. the counteracting antioxi-
dants. In CKD, such stress is multifactorial. Uremic
toxins, interactions between circulating mononuclear
cells and bioincompatible dialyzers or contaminated di-
alysate, and infections, can act as triggers [12]. In
addition, dialysis patients have reduced levels of vitamins
C and E, selenium, and β-carotene, and they show low-
ered antioxidant enzyme activities; paraoxonase, catalase,
superoxide dismutase, heme oxygenase and glutathione
peroxidase [13]. Although increased oxidative stress is
increasingly recognized as an important metabolic event
in adults with CKD [14], there are few studies utilizing
global biomarkers of oxidative stress in children with
CKD [15,16].
To our knowledge, there are a few studies addressing
systemic oxidative stress and cellular hypoxia biomarkers
together in children with CKD on regular hemodialysis.
We suggested that impaired response to tissue hypoxia
and oxidative stress would be major determinants to
clinical outcomes in such patients. This cross-sectional
study aimed at assessing the effect of CKD as well as
maintenance HD on plasma oxidative stress markers
[total anti-oxidant capacity (TAC), total peroxide (TPX)and oxidative stress index (OSI)] and standard hypoxia
biomarkers [lactate, pyruvate and lactate/pyruvate (L/P)
ratio, and VEGF] as well as HIF-1α in CKD pediatric
patients before and after HD session. HIF-1α, the key
regulatory cellular hypoxia effector is investigated for
the first-time to our knowledge as a plasma biomarker.




Forty children and adolescents with CKD (25 male and
15 female) on maintenance HD with an age range of
6–15 years [12.83±1.89 years, mean+/− standard devi-
ation (SD)] were voluntarily recruited to this cross sec-
tion study at the Pediatric Nephrology and Dialysis
Unit, Assiut Children University Hospital, Assiut, Egypt,
during the period from January 2010 to September
2010. At the time of the study, all the patients were on
regular three HD sessions per week; each time for 3–4 h
(total 12 h weekly) for more than 3 months with polysul-
fone dialyzing membranes, after creatinine clearance
had fallen below 8–12 mL/min and/or pharmaco-
logical treatment and diet had proved inadequate to
control clinical symptoms. The mean dialysis duration
was 2.18±1.36 years (range: 1–7 years). All patients were
on dietary protein restriction, 1 g/kg body weight per
day. The dialysate used was a standard ionic compos-
ition and bicarbonate-based buffer (Na+ 138 mmol/L,
HCO3
- 36.6 mmol/L, K+ 1.5 mmol/L, Ca2+ 1.25 to
1.75 mmol/L, Mg2+ 0.75 mmol/L) for all cases. The
blood flow was 120–150 mL/min and dialysis fluid was
used at a flow rate of 240–300 mL/min. Vascular access
was arteriovenous fistula in the upper limbs. The causes
of CKD were: urolithiasis (n= 11), recurrent pyeloneph-
ritis with vesico-ureteral reflux (n= 8), chronic glomeru-
lopathies (n = 16), hypoplastic-dysplastic kidney (n = 2),
posterior urethral valve (n= 2) and cystinosis (n= 1). The
healthy control group consisted of 20 age- and sex-
matching volunteers aging 6–15 years (12.10±2.59 years)
from those admitted for routine check-up.
At the time of entry, none of the participants was re-
ceiving non-steroidal anti-inflammatory drugs, immuno-
suppressive therapy or any other drugs that might have
interfered with the oxidative stress, and none had un-
controlled hypertension or a history of seizure. Patients
with infections, vasculitides, or respiratory, metabolic
and hepatic diseases were excluded. Control subjects
were on a normal diet without vitamin supplementation
and were free from any infection or medication. Routine
analyses showed that controls had normal renal function
tests and no disorders of lipid metabolism. Both patients
and controls were nonsmokers. The study was approved
by the local ethics committee and was conducted in
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informed consent was obtained in every case from their
legal guardians. Demographic, clinical and biochemical
characteristics of all participants were reported.Laboratory investigations
Blood samples (5 mL) with and without EDTA/sodium
fluoride as anticoagulant were obtained via venipuncture
after the participants had fasted overnight (between 8.30
P.M. and 9.30 A.M.), and serum and plasma were sepa-
rated and aliquot frozen at −80°C till used. In HD
patients, venous blood samples were drawn immediately
before and after hemodialysis session. Baseline labora-
tory investigations were carried out for all patients and
controls including complete blood count, serum urea
and creatinine, arterial pH, arterial blood gases and in-
fection screening, which included blood and urinary cul-
tures by standard methods. Arterial pH, PaO2, PaCO2,
HCO3
- were determined using a pH/blood gas analyzer
on anaerobically collected blood drawn in ice-cold,
heparinized glass syringes.
ELISA assays were utilized to measure each of VEGF
(Cat# ELH-VEGF-001, RayBiotech, Inc, Norcross GA
30092 - lower detection limit is 10 pg/mL) and HIF-1α
(Cat# DYC1935-5, R&D Systems, Minneapolis, MN
55413, USA - lower detection limit is 3 pg/mL) with
specific capture and biotinylated detection antibodies
and Streptavidin-Horse Radish Peroxidase/tetramethyl-
benzidine as the detection system. Total antioxidant cap-
acity was estimated according to the colorimetric
method of Koracevic et al. [17] with uric acid as stand-
ard. Total plasma peroxide concentrations were deter-
mined using the colorimetric FOX2 method with H2O2
standard as modified by Harma et al. [18]. Briefly, 250
μM FOX2 reagent (9.8 mg ammonium ferrous sulfate in
10 mL of 250 mmol H2SO4 was added to 90 mL HPLC-
grade methanol containing 79.2 mg butylated hydroxyto-
luene, finally, 7.6 mg xylenol orange was added. The
blank reagent is devoted of ferrous sulfate. 200 μL of
plasma was incubated with 1.8 mL FOX2 or blank re-
agent at room temperature for 30 min. Tubes were cen-
trifuged at 12,000g for 10 min and absorbance of clear
supernatant was determined at 560 nm vs. blank. The
coefficient of variation for individual plasma samples
was less than 5%. Percent ratio of TPX to TAC level
is the oxidative stress index (OSI; = TPX, μmol/L/
TAC, μmol/L X 100) [18,19]. Pyruvate was measured
following the decrease in UV-absorbance of NADH.H+
according to instructions of the manufacturer (Cat# 180 000,
Greiner Diagnostics GmbH, D-79353 Bahlingen, Ger-
many). Lactate was colorimetrically measured using
lactate oxidase/peroxidase/tribromo-hydroxybenzoic acid-
4-aminoantipyrine according to instructions of themanufacturer (Cat# 274 001, Spectrum Biodiagnostics,
Cairo, Egypt). Lactate/pyruvate ratio was calculated.
Data analysis
Statistical Science for Social Package (SPSS Inc, USA)
software computer program version 12 was used for
data analysis. Data were presented as mean -/+ SD and
minimum - maximum or number and percentage (n, %)
as appropriate. For comparison of two groups the non-
parametric test for independent variables and paired and
unpaired student “t” test for parametric variables were
used while, comparisons of multiple groups were done
using one-way analysis of variation for parametric vari-
ables. Spearman’s correlation test was used for paramet-
ric variables within each group. For all tests, a
probability (P) <0.05 was considered significant.
Results
Table 1 showed relevant participants’ characteristics.
Compare to healthy controls, hemoglobin, pH, PCO2
and HCO3
- were significantly higher (P <0.001) while, cre-
atinine, urea and PCO2 were significantly lower (P <0.001)
than patients.
Total antioxidant capacity was significantly lower
while TPX, OSI and VEGF were significantly higher in
patients at before- and after-dialysis session than healthy
controls. Lactate and HIF-1α levels were significantly
higher (P <0.019, P <0.002) at before-dialysis session
compared to healthy controls. Before dialysis, TAC and
L/P ratio were higher (P <0.036, P <0.001) compared to
after-dialysis level (Table 2).
At before-dialysis session, duration of disease posi-
tively correlated with HIP-1α (r = 0.677, P <0.001) but
negatively correlated with VEGF (r = −0.486, P < 0.001);
VEGF positively correlated with each of pyruvate
(r = 0.316, P <0.047) and HIF-1α (r = 0.374, P <0.018),
and, OSI positively correlated with TPX (r = 0.969,
P <0.001), but, negatively correlated with TAC (r = −0.469,
P <0.002). At after-dialysis session, HIF-1α negatively
correlated with each of TPX (r = −0.529, P <0.001) and
OSI (r = −0.459, P <0.003); while, OSI positively corre-
lated with TPX (r = 0.944, P <0.001) (Table 3).
Discussion
Relative hypoxia, as the major activator of hypoxia-
inducible factor, is detectable in chronic kidney disease
tissues irrespective of etiology and is thought to result
from a combination of structural and functional changes
that include; decreased peritubular blood flow associated
with glomerular injury, capillary rarefaction, vasocon-
striction, luminal narrowing of atherosclerotic vessels,
increased oxygen demand from hyperfiltration and tubu-
lar hypertrophy, limited oxygen diffusion as a conse-
quence of extracellular matrix expansion, and renal








Age (years) 12.10 ± 2.59 12.83 ± 1.89 0.126
6.00 - 15.00 6.00 - 15.00
Gender
Male 10 (50.00%) 25 (62.50%)
Female 10 (50.00%) 15 (37.50%)
Time on
hemodialysis (years)
- 2.18 ± 1.36 -
1.00 - 7.00
Hemoglobin (gram/dL) 11.50 ± 0.94 9.35 ± 0.85 0.001
10.00 - 12.90 8.70 - 11.60
Creatinine (μmol/L) 93.6 ± 22.41 468.00 ± 177.55 0.001
58.00 - 127.00 157.00 - 750.00
Urea (mg/dL) 22.90 ± 5.64 196.10 ± 23.50 0.001
15.00 - 32.00 150.00 - 229.00
pH 7.39 ± 0.02 7.32 ± 0.02 0.001
7.35 - 7.40 7.30 - 7.35
PCO2 (mmHg) 38.95 ± 1.10 31.74 ± 6.92 0.001
37.00 - 40.00 18.20 - 43.10
PO2 (mmHg) 87.59 ± 11.5 112.56 ± 24.35 0.001
88.00 - 96.00 87.00 - 169.00
HCO3
- (μmol/L) 22.90 ± 0.64 15.66 ± 4.13 0.001
22.00 - 24.00 8.10 - 21.20
Data are express as mean ± SD minimum - maximum or number (%);
significance versus controls.
Table 2 Changes in the plasma levels of the investigated










0.66 ± 0.05 0.60 ± 0.05 0.57 ± 0.06




30.50 ± 12.76 38.50 ± 12.52 37.25 ± 12.92
*P <0.021 *P <0.050
**P = 0.673
Oxidative stress index 4.63 ± 1.89 6.52 ± 2.30 6.53 ± 2.23
*P <0.002 *P <0.002
**P = 0.983
Lactate (mg/dL) 12.06 ± 3.66 15.90 ± 6.56 13.34 ± 5.99
*P <0.019 *P = 0.425
**P = 0.061
Pyruvate (mg/dL) 5.02 ± 3.67 6.47 ± 8.69 6.84 ± 4.02
*P = 0.402 *P = 0.280
**P = 0.777
Lactate/pyruvate ratio 3.36 ± 1.69 4.07 ± 2.70 2.57 ± 1.76




4.00 ± 1.26 32.91 ± 24.40 33.15±24.58




29.45 ± 10.07 57.02 ± 41.86 43.29 ± 26.67
*P <0.002 *P = 0.115
**P = 0.120
Data shown are mean ± SD mean -/+ SD (minimum - maximum); *P:
significance vs. healthy controls; **P: significance vs. before-dialysis session.
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unique situation because their survival is dependent
upon treatments which are operational only 12–18 h per
week in six hour sessions. This procedure subjects these
patients to innumerable abrupt alterations in the internal
environment, especially rapid shifts in pH [21]. In this
study, the before-dialysis levels of plasma lactate, HIF-1α
and VEGF were significantly higher compared to healthy
controls while, lactate/pyruvate ratio was significantly
higher compared to after-dialysis level. The lactate level
tended to fall with dialysis, at least in part attributable to
this procedure. Also, VEGF plasma level was signifi-
cantly elevated in after-dialysis session compared to
healthy controls. Hypoxia is accompanied by a signifi-
cant increase in blood lactate and severe systemic
acidosis as a direct effect of anaerobic metabolism.
Beside the direct effects of anaerobic metabolism,
catecholamine-induced stimulation of cellular glycolysis
and subsequent synthesis of lactate worsens the
increased systemic lactate. In such conditions, accumu-
lated pyruvate is metabolized into lactate. Determination
of the lactate/pyruvate ratio thus provides a more accur-
ate statement of tissue metabolism and the cytosolic
redox condition [22]. As a correction measure, hypoxia-induced HIF-1 upregulates the expression of monocar-
boxylate transporter 4, which mediates lactic acid efflux,
and of membrane-bound carbonic anhydrase IX, which
catalyzes the conversion of extracellular CO2 to carbonic
acid. The latter contributes to the acidification of the
extracellular space and enables an increase in intracellu-
lar pH through the subsequent uptake of HCO3
- (a weak
base). HIF-1 directly activates the expression of several
pro-angiogenic factors, the best characterized of which
is VEGF. This event promotes the formation of new
blood vessels, thus restoring the supply of oxygen and
nutrients [23]. Increased HIF expression has been found
in animal models of CKD and in renal biopsy material
from patients with diabetic nephropathy and other forms
of renal disease [20,24,25].
In this study, HIF-1α was investigated as a plasma bio-
marker for the first-time world-wide particularly in
CKD. At before-dialysis session, plasma VEGF positively
correlated with each of pyruvate, and HIF-1α. The posi-
tive correlation between HIF-1α and VEGF is expected
Table 3 Correlations among the measured parameters in CKD patients at before- and after-dialysis settings
Parameters Duration Lactate Pyruvate Lactate/Pyruvate
ratio





Before dialysis −0.193(0.234) 0.282(0.078)
After dialysis −0.095(0.580) 0.533(0.001)
Lactate/pyruvate ratio
Before dialysis −0.067(0.640) 0.513(0.001) −0.457(0.003)
After dialysis −0.037(0.824) 0.212(0.188) −0.630(0.001)
HIF-1α
Before dialysis 0.677 (0.001) 0.125(0.442) −0.149(0.359) 0.220(0.173)
After dialysis −0.186(0.249) 0.048(0.770) 0.015(0.929) 0.229(0.156)
VEGF
Before dialysis −0.486(0.001) 0.291(0.069) 0.316(0.047) 0.027(0.866) 0.374(0.018)
After dialysis 0.189 (0.243) 0.125 (0.441) 0.059(0718) 0.098(0.545) −0.163(0.314)
TAC
Before dialysis 0.265 (0.098) −0.174(0.283) −0.147(0.366) −0.142(0.384) 0.068(0.676) −0.206(0.202)
After dialysis 0.022 (0.894) 0.048(0.771) −0.148(0.361) 0.105(0.517) −0.220(0.173) −0147(0.366)
Total peroxides
Before dialysis −0.017(0.918) −0.032(0.843) −0.194(0.230) 0.128(0.430) −0.138(0.394) 0.229(0.156) −0.247(0.124)
After dialysis 0.283 (0.077) 0.036(0.825) 0.070(0.668) −0.204(0.207) −0.529(0.001) −0.006(0.972) 0.168(0.301)
Oxidative stress index
Before dialysis −0.093(0.566) −0.002(0.989) 0.161(0.322) 0.156(0.337) −0.172(0.287) 0.245(0.128) −0.469(0.002) 0.969(0.001)
After dialysis 0.285 (0.075) 0.015(0.929) 0.113(0.489) −0.240(0.136) −0.459(0.003) 0.062(0.705) −0.155(0.340) 0.944(0.001)
Data shown are r value (P< value). HIF-1α= hypoxia induced factor-1α, VEGF= vascular endothelial growth factor. TAC = total antioxidant capacity.
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gen delivery to tissues. This indicates the utility of HIF-
1α as plasma biomarker of cellular hypoxia in CKD that
reflects the disease outcomes. However, a reparative role
for the induced HIF-1 in CKD is questionable in light of
blockade of the induction of erythropoietin by the accu-
mulating uremic toxins [11,26-28].
The role of ROS and/or decreased antioxidant activity
in the development of CKD complications, such as ath-
erosclerosis and related cardiovascular disturbances is
well-established [14]. In this study children with CKD
showed increased plasma TPX and OSI and decreased
TAC levels at both of before- and after-dialysis com-
pared to healthy controls. Increased oxidative stress has
been reported in numerous adult studies in patients with
CKD [29]. However, there are few reports on the
anti-oxidant system in children with CKD [15,30,31].
Zwolińska et al. [15] reported increased lipid peroxida-
tion, monitored by plasma and erythrocyte malondialde-
hyde (MDA), together with decreased superoxide
dismutase, catalase and glutathione peroxidase activities
in children with chronic renal failure before-dialysis as
compared to healthy age-matched subjects. The resultsof our study show significant decreased in TAC levels in
after-dialysis compared to before-dialysis which may be
related to the loss of antioxidants during dialysis. Turi
et al. [32] observed an increase of erythrocytic-MDA in
HD children. Daschner et al. [33] showed high plasma
MDA levels in a group of ten pediatric patients on HD
and in eleven children on peritoneal dialysis. Other stud-
ies indicate an impairment of antioxidant systems and
augmentation of oxidants during HD sessions in adult
patients with end stage renal diseases [34-36].
One reason for oxidative stress in patients with renal
failure is the underlying disease itself. Renal toxicity and
immunological disorders of the kidney result in an ele-
vated formation of ROS which is active in the pathogen-
esis of kidney disease. However, treatment procedures
were also shown to induce oxidative stress. During HD,
incomplete correction of the uremic toxicity together
with the untoward effects of dialysis, malnutrition and
the progressive worsening of clinical condition, can lead
to oxidative stress. The later is caused by an abnormal
production of oxidants including ROS and uremic
toxins with pro-oxidant function correlating defective
antioxidant protection. Bioincompatibility of dialysis
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Losses of antioxidants via dialysis are the factors that
may be responsible for the imbalance between pro-
oxidative and antioxidative mechanisms in HD patients
[37]. Total antioxidant capacity in renal failure group is
diminished to a great extent due to antioxidant exhaus-
tion and inhibition [38]. Oxidative stress can also accel-
erate the apoptosis of leukocytes in HD patients [39].
The activation of neutrophils and the complement path-
way during HD session as the result of interactions of
the blood with the dialysis membrane and endotoxin
contaminated dialysate, iron overload, the presence of
advanced glycation end products, high homocysteine
levels, intradialytic cytokine activation, among others,
could play a role [40].
However, Drai et al. [41] reported that chronic renal
disease patients admitted to HD, presented enhanced
levels of MDA and oxidized glutathione, and decreased
concentrations of glutathione and glutathione peroxid-
ase, without any changes in plasma levels of TAC, vita-
mins A and E. Another clinical study reported that TAC
measured as Trolox equivalents was higher in HD
patients compared with control group. Although MDA
and 4-hydroxynonenal levels were also increased,
plasma thiols were lower and α-tocopherol was not
altered [42]. After HD, plasma levels of thiols, MDA,
4-hydroxynonenal and TAC were normalized. Similar
results were found by Samouilidou and Grapsa [43].
Difference in the biomarker used and dietary antioxi-
dant supplementations could be a major cause of such
discrepancy.
In our healthy controls, L/P ratio positively correlated
TAC; HIF-1α positively correlated with each of L/P ratio
and TAC; VEGF positively correlated with each of TPX
and OSI. At after-dialysis, HIF-1α negatively correlated
with each of TPX and OSI. In this respect, several
reports showed an inverse correlation between MDA
serum concentration and hemoglobin in the blood of
HD patients [29,31]. A recent report connected induced
HIF-1α and increases in reactive O2 species [44]. The
accelerated LPO at the low Hb level might be explained
by oxidative stress due to the anemic condition itself.
Anemic patients showed an increased frequency of ven-
tilation at peak exercise because of the limited oxygen
transport capacity, implying anaerobic metabolism due
to hypoxemia and ischemia. It is possible to suggest that
hypoxic patients showing high HIF-1α would have good
prognosis since their cellular response to hypoxia is
functional - providing that downstream effectors such as
VEGF and erythropoietin are activated.
Conclusion
There is considerable cellular hypoxia in pediatric
patients with CKD that leads to oxidative stress. HDleads to decrease hypoxia and increase loss of antioxi-
dants as evidenced by decreased levels of HIF-1α and
TAC at before- compared to after-dialysis settings. The
resulting oxidative stress could contribute to the long-
term complications in uremic patients. In compensation,
VEGF levels increases to improve oxygen delivery to
hypoxic tissue. Further longitudinal studies are necessary
to establish the relationship between plasma markers of
hypoxia and oxidative stress and clinical outcomes of
CKD on maintained HD - particularly utilizing interven-
tions such as antioxidant supplements and improved
aeriation. Longitudinal studies are mandatory since pre-
liminary data showed that low blood gases and
hemoglobin correlating with high hypoxia biomarkers
are fatal.
Limitation of the study
Our study has several limitations that necessitate further
investigations. By nature, a cross-sectional study would
not derive a cause/effect conclusion among the investi-
gated parameters and CKD and/or HD. Second, blood
gases, pH and bicarbonate were analyzed before dialysis
only because of local limitations. Third, the limited
number of participants did not allow statistically mean-
ingful subgrouping according to underlying cause of
CDK.
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